During the last session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares were 0.72 million, with the beta value of the company hitting 0.43. At the end of the trading day, the stock’s price was $0.26, reflecting an intraday gain of 5.76% or $0.02. The 52-week high for the BCLI share is $1.81, that puts it down -596.15 from that peak though still a striking 50.0% gain since the share price plummeted to a 52-week low of $0.13. The company’s market capitalization is $20.65M, and the average intraday trading volume over the past 10 days was 0.48 million shares, and the average trade volume was 552.68K shares over the past three months.

Brainstorm Cell Therapeutics, Inc. (BCLI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. BCLI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.03.

Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information

Brainstorm Cell Therapeutics, Inc. (BCLI) registered a 5.76% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 5.76% in intraday trading to $0.26, hitting a weekly high. The stock’s 5-day price performance is -19.67%, and it has moved by -35.25% in 30 days. Based on these gigs, the overall price performance for the year is -83.71%. The short interest in Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is 1.08 million shares and it means that shorts have 1.71 day(s) to cover.

Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts

Statistics show that Brainstorm Cell Therapeutics, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Brainstorm Cell Therapeutics, Inc. (BCLI) shares have gone down -33.91% during the last six months, with a year-to-date growth rate more than the industry average at 72.55% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 76.90% this quarter and then jump 78.60% in the quarter after that.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.57%. While earnings are projected to return 65.00% in 2024.

BCLI Dividends

Brainstorm Cell Therapeutics, Inc. is due to release its next quarterly earnings 2024-Aug-14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s Major holders

Brainstorm Cell Therapeutics, Inc. insiders own 9.05% of total outstanding shares while institutional holders control 5.07%, with the float percentage being 5.58%. VANGUARD GROUP INC is the largest shareholder of the company, while 53.0 institutions own stock in it. As of 2024-03-31, the company held over 1.4 million shares (or 2.7779% of all shares), a total value of $0.79 million in shares.

The next largest institutional holding, with 0.49 million shares, is of BLACKROCK INC.’s that is approximately 0.9702% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $0.28 million.

Also, the Mutual Funds coming in first place with the largest holdings of Brainstorm Cell Therapeutics, Inc. (BCLI) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Mar 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 951.37 shares. This amounts to just over 1.19 percent of the company’s overall shares, with a $0.25 million market value. The same data shows that the other fund manager holds slightly less at 401.01, or about 0.50% of the stock, which is worth about $0.1 million.